Filipsson Helena, Monson John P, Koltowska-Häggström Maria, Mattsson Anders, Johannsson Gudmundur
Department of Endocrinology, Gröna Stråket 8, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden.
J Clin Endocrinol Metab. 2006 Oct;91(10):3954-61. doi: 10.1210/jc.2006-0524. Epub 2006 Aug 8.
Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid (GC) share certain clinical features.
The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy.
A total of 2424 hypopituitary patients within the KIMS (Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age.
At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects.
HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
未治疗的生长激素缺乏的垂体功能减退患者与接受不适当高剂量糖皮质激素(GC)治疗的患者具有某些共同的临床特征。
本研究旨在探讨生长激素替代治疗前后,GC替代治疗对垂体功能减退患者临床特征的影响。
在辉瑞国际代谢数据库(KIMS)中,根据促肾上腺皮质激素(ACTH)状态,将2424例垂体功能减退患者进行分组。比较接受氢化可的松(HC)(n = 1186)、醋酸可的松(CA)(n = 487)、泼尼松龙/地塞米松(n = 52)治疗的患者与ACTH功能正常患者(AS)(n = 717)在接受1年生长激素治疗前后的体重指数、腰围和臀围、血压、血糖、糖化血红蛋白(HbA1c)、血脂、胰岛素样生长因子-Ⅰ(IGF-Ⅰ)及合并症情况。计算氢化可的松等效剂量(HCeq),并根据性别和年龄对测量值进行校正。
基线时,与ACTH功能正常患者相比,HC组总胆固醇、甘油三酯、腰围和HbA1c升高,泼尼松龙/地塞米松组腰臀比升高。在调整HCeq剂量后,HC组的HbA1c仍高于CA组。接受GC治疗的患者血清IGF-Ⅰ、体重指数、甘油三酯、低密度脂蛋白胆固醇和总胆固醇水平呈剂量依赖性升高。基线时HCeq剂量小于20mg/d的患者(n = 328)在代谢指标方面与ACTH功能正常患者无差异。所有GC组和剂量类别对生长激素的1年代谢反应相似。生长激素治疗期间所有新发糖尿病病例(n = 12)、中风病例(n = 8)和心肌梗死病例(n = 3)均发生在接受GC治疗的患者中。
垂体功能减退的成年患者HCeq剂量至少为20mg/d与不良代谢状况相关。与其他GC相比,CA替代治疗可能具有代谢优势。